en.Wedoany.com Reported - Recently, Mevion Medical Systems announced two significant collaborations, establishing partnerships with the G. Pascale Foundation National Cancer Institute and Vietnam's Tan An General Hospital to install the MEVION S250-FIT proton therapy system.
The G. Pascale Foundation National Cancer Institute in Italy selected Mevion to provide the MEVION S250‑FIT system through a European public tender. Upon completion, the project will become the first proton therapy center in Southern Italy, effectively improving the current situation where proton therapy resources are concentrated in the north, requiring patients to travel across regions for treatment, and contributing to a balanced allocation of regional medical resources.
The center adopts an integrated delivery solution, collaboratively advanced by Mevion Medical Systems, Leo Cancer Care, and Morviducci, with RaySearch providing the treatment planning and oncology information system. It can be directly installed in an existing linear accelerator vault without the need for large-scale construction, enabling clinical deployment with smaller space, lower cost, and faster speed.
Vietnam's Tan An General Hospital has officially procured the MEVION S250‑FIT system, marking the first signed contract for a proton therapy system in Vietnam. It is expected to become operational by the end of 2027, coinciding with the opening of the hospital's new facility.
Vietnam has only 84 linear accelerators nationwide, meeting only 60% to 70% of basic needs, many of which have been in use for 10-15 years. In 2025, the Vietnamese Ministry of Health designated relevant units to build proton therapy centers at three major hospitals in the northern, central, and southern regions. These projects are expected to complete investment preparations in 2025, with a target for completion between 2026 and 2030. For details, see the previous report by Proton China, "Vietnam to Build Three Proton Therapy Centers."
Currently, the MEVION S250-FIT has been adopted by multiple U.S. institutions, including Stanford Health Care and the Dana‑Farber Cancer Institute. This simultaneous deployment in Europe and Asia further validates the clinical strength and global adaptability of the integrated proton therapy solution.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
